ArticleScientific reports2017
Transforming Growth Factor-beta Regulation of Ephrin Type-A Receptor 4 Signaling in Breast Cancer Cellular Migration.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Connexin 32 constrains a mesenchymal-like switch in differentiated urothelium and luminal cancers.Life science alliance · 2026Article
- Article
- The role of chloride intracellular channel 4 in tumors.Cancer cell international · 2025Review
- Comprehensive analysis of Epha10 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in non-small cell lung cancer.Scientific reports · 2024Article
- Neurodegeneration-associated protein VAPB regulates proliferation in medulloblastoma.Scientific reports · 2023Article
- Unraveling the Potential of EphA4: A Breakthrough Target and Beacon of Hope for Neurological Diseases.Cellular and molecular neurobiology · 2023Review
- Host CLIC4 expression in the tumor microenvironment is essential for breast cancer metastatic competence.PLoS genetics · 2022Article
- The genomic and transcriptional landscape of primary central nervous system lymphoma.Nature communications · 2022Article
- EPHA2, EPHA4, and EPHA7 Expression in Triple-Negative Breast Cancer.Diagnostics (Basel, Switzerland) · 2022Article
- The Clinical Impact of the EPH/Ephrin System in Cancer: Unwinding the Thread.International journal of molecular sciences · 2021Review
- A cancer mutation promotes EphA4 oligomerization and signaling by altering the conformation of the SAM domain.The Journal of biological chemistry · 2021Article
- Hypoxia acts as an environmental cue for the human tissue-resident memory T cell differentiation program.JCI insight · 2021Article
- SOX4 and SMARCA4 cooperatively regulate PI3k signaling through transcriptional activation of TGFBR2.NPJ breast cancer · 2021Article
- Single-cell transcriptome analysis revealed the heterogeneity and microenvironment of gastrointestinal stromal tumors.Cancer science · 2021Article
- The Role of the Eph Receptor Family in Tumorigenesis.Cancers · 2021Review
- The Expression Profile and Prognostic Values of EPHA Family Members in Breast Cancer.Frontiers in oncology · 2021Article
- Expression Pattern and Prognostic Value of EPHA/EFNA in Breast Cancer by Bioinformatics Analysis: Revealing Its Importance in Chemotherapy.BioMed research international · 2021Article
- Structural health monitoring of metal-to-glass-ceramics penetration during thermal cycling aging using femto-laser inscribed FBG sensors.Scientific reports · 2020Article
- Low-Frequency Magnetic Fields (LF-MFs) Inhibit Proliferation by Triggering Apoptosis and Altering Cell Cycle Distribution in Breast Cancer Cells.International journal of molecular sciences · 2020Article
- A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers.Cancers · 2019Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
Abstract
Breast cancer consists of a range of tumor subtypes with different clinical characteristics, disease prognosis, and treatment-response. Luminal breast cancer has the best prognosis while basal-like breast cancer (BLBC) represents the worst subtype. Transforming growth factor-beta (TGFβ) plays a prominent role in stimulating the migration and invasion of malignant breast cancer cells contributing to tumor progression. In this study, we identified the Ephrin type-A receptor 4 (EPHA4) as a novel target of TGFβ in breast cancer. Moreover, we show that TGFβ induction of EPHA4 gene expression is specific to basal-like tumors and is required for TGFβ-mediated cell migration. We further addressed the mechanism and found EPHA4 to be required for TGFβ-mediated cell migration in breast cancer through TGFβ-induced short term and long term activation of RhoGTPases. Finally, our data revealed a strong association between high EPHA4 expression and advanced tumor stage, aggressive BLBC molecular subtype and poor prognosis. Importantly, we found significant co-expression of EPHA4 and the TGFβ receptor type-2 (TGFβR2) in breast cancer subtypes associated with increased tumor relapse and drug resistance. Together, this study highlight the important role of the TGFβ/EPHA4 signaling axis in mediating tumor aggressiveness and poor patient survival in human breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.